Table 2.

Comparison of major platforms incorporating CRISPR/Cas-based 13

System name	Effector	Recognition type	Sensitivity	Specificity	Signal amplification	Quantitative	Multiplex	Time	Readout	Infrastructure requirement	Reference
SHERLOCKv1	LwaCas13a	DNA/Virus RNA	aM	1 nt	RPA	N	Na	2–5 h	Fluorescence	Substantial	[54]
SHERLOCKv2	LwaCas13a, Cca-Cas13b, Psm-Cas13b	DNA/Virus RNA	zM	1 nt	RPA	Yb	Y	~  1 h	Fluorescence, Naked-eye observation	Substantial/Few	[15]
m1A detection	LbuCas13a	m1A-RNA	fM	1 nt	N	Y	N	~ 10 min	Fluorescence	Substantial	[55]
On-for-all Biosensor	LwaCas13a	Tumor marker miRNA	pM	1 nt	N	Y	N	~  4 h	Electrochemical signal	Few	[20]
POC system	LwaCas13a	Ebola RNA	20 pfu	1 nt	N	Y	N	~  5 min	Fluorescence	Substantial	[14]
Colorimetric platform	LwaCas13a	Virus RNA	200 copies	1 nt	N	Y	N	~  1 h	Naked eye observation	Few	[13]

a: zM, 10⁻²¹ M or zeptomole/L; aM, 10⁻¹⁸ M or attomole/L; fM, 10⁻¹⁵ M or femtomole/L; N, no; NA, not applicable; nt, nucleotide; Y, yes. b: Scale level quantitative results achieved. CLISA: CRISPR/Cas13a signal amplification-linked immunosorbent assay